group IID sPLA2 CRISPR/Cas9 KO Plasmid (m): sc-422283
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- group IID sPLA2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the group IID sPLA2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
group IID sPLA2 CRISPR/Cas9 KO Plasmid (m) | sc-422283 | 20 µg | $397.00 |
Overview
Pla2g2d encodes group IID secreted phospholipase A2 (sPLA2), an extracellular enzyme that hydrolyzes membrane phospholipids to release free fatty acids and lysophospholipids, shaping lipid mediator pools that feed into eicosanoid and related signaling pathways. In mouse tissues enriched for immune activity, group IID sPLA2 contributes to regulation of inflammatory tone by modulating antigen-presenting cell function, cytokine programs, and resolution-associated lipid networks. Through effects on arachidonic acid availability and downstream prostaglandin/leukotriene biosynthesis, Pla2g2d links phospholipid remodeling to innate and adaptive immune crosstalk. Dysregulated expression or activity has been associated with altered susceptibility to inflammatory pathologies and immune-driven tissue remodeling in preclinical models.
group IID sPLA2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Pla2g2d gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Pla2g2d together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Pla2g2d open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish group IID sPLA2 protein expression.
This CRISPR knockout system enables efficient generation of Pla2g2d-deficient cell models for investigation of group IID sPLA2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Pla2g2d exon(s) critical for group IID sPLA2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Pla2g2d genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by group IID sPLA2 CRISPR/Cas9 KO Plasmid (m) and group IID sPLA2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Pla2g2d locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by group IID sPLA2 HDR Plasmid (m) and group IID sPLA2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Pla2g2d homology arms to support homology-directed repair at defined Pla2g2d target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.